StreetInsider.com News Articles

Zealand Pharma's petrelintide shows weight loss in Type 2 diabetes trial

Wed, 07 Oct 2026 13:14:15 -0400

Zealand Pharma A/S (Nasdaq: ZEAL) reported positive topline results from its Phase 2 ZUPREME-2 trial, in which the amylin analog petrelintide achieved up to 9.2% mean body weight reduction at week 28 compared with 2.0% for placebo in participants with overweight or obesity and type 2 diabetes.

The randomized, double-blind, placebo-controlled trial enrolled 220 participants in the United States, with a mean baseline BMI of 36.3 kg/m² and mean baseline HbA1c of 8.0%. Participants received once-weekly subcutaneous injections of petrelintide, escalated every four weeks, alongside a reduced-calorie diet and increased physical activity. The trial met its primary endpoint across all three

Zealand Pharma announces positive Phase 2 ZUPREME-2 topline results for amylin analog petrelintide in people with overweight or obesity and type 2 diabetes

Wed, 07 Oct 2026 13:13:53 -0400

Company announcement – No. 54 / 2026

Zealand Pharma announces positive Phase 2 ZUPREME-2 topline results for amylin analog petrelintide in people with overweight or obesity and type 2 diabetes

Petrelintide achieved up to 9.2% mean body weight reduction at week 28 versus 2.0% with placebo
At week 28, petrelintide demonstrated a HbA1c reduction of up to 0.65% versus an increase of 0.23% with placebo
Safety and tolerability profile of petrelintide was consistent with that seen in the Phase 2 ZUPREME-1 trial
Very low discontinuation rates due to gastrointestinal adverse events

Zealand Pharma announces positive Phase 2 ZUPREME-2 topline results for amylin analog petrelintide in people with overweight or obesity and type 2 diabetes

Wed, 07 Oct 2026 13:13:53 -0400

Company announcement – No. 54 / 2026

Zealand Pharma announces positive Phase 2 ZUPREME-2 topline results for amylin analog petrelintide in people with overweight or obesity and type 2 diabetes

Petrelintide achieved up to 9.2% mean body weight reduction at week 28 versus 2.0% with placebo
At week 28, petrelintide demonstrated a HbA1c reduction of up to 0.65% versus an increase of 0.23% with placebo
Safety and tolerability profile of petrelintide was consistent with that seen in the Phase 2 ZUPREME-1 trial
Very low discontinuation rates due to gastrointestinal adverse events

Zealand Pharma – Completion of share buy-back program and related transactions (week 40 and 41, 2026)

Mon, 05 Oct 2026 12:30:00 -0400

Company announcement No. 53 / 2026

Zealand Pharma - Completion of share buy-back program and related transactions (week 40 and 41, 2026)

Copenhagen, Denmark, October 5, 2026 – Zealand Pharma A/S ("the Company" or “Zealand Pharma”) (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, today announces that the share buy-back program (the "Program") initiated on May 7, 2026 has been completed. The lead manager, Danske Bank, exercised its option to close the Program ahead of October 31, 2026, after the planned aggregate amount of approximately DKK 1,300 million was reached.

Zealand Pharma – Completion of share buy-back program and related transactions (week 40 and 41, 2026)

Mon, 05 Oct 2026 12:30:00 -0400

Company announcement No. 53 / 2026

Zealand Pharma - Completion of share buy-back program and related transactions (week 40 and 41, 2026)

Zealand Pharma announces opening of new Research Hub in Cambridge, Massachusetts

Thu, 01 Oct 2026 09:30:00 -0400

Press release – No. 19 / 2026

Zealand Pharma announces opening of new Research Hub in Cambridge, Massachusetts

Builds on the Metabolic Frontier 2030 strategy, advancing its ambition to become a leader in obesity and metabolic health
Ribbon-cutting ceremony marks the official opening of the Company’s primary U.S. address, expanding Zealand Pharma’s global research platform

Copenhagen, Denmark, and Boston, Massachusetts, September 30, 2026 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, today celebrated the opening of its new research hub at 35

Zealand Pharma announces opening of new Research Hub in Cambridge, Massachusetts

Thu, 01 Oct 2026 09:30:00 -0400

Press release – No. 19 / 2026

Zealand Pharma announces opening of new Research Hub in Cambridge, Massachusetts

Builds on the Metabolic Frontier 2030 strategy, advancing its ambition to become a leader in obesity and metabolic health
Ribbon-cutting ceremony marks the official opening of the Company’s primary U.S. address, expanding Zealand Pharma’s global research platform

Zealand Pharma announces Boehringer Ingelheim’s survodutide achieves up to 13.1% weight loss in new Phase III trial, alongside significant improvements in glycemic control in people with obesity and

Thu, 01 Oct 2026 03:30:00 -0400

Company announcement – No. 52 / 2026

Zealand Pharma announces Boehringer Ingelheim’s survodutide achieves up to 13.1% weight loss in new Phase III trial, alongside significant improvements in glycemic control in people with obesity and type 2 diabetes

In the SYNCHRONIZE-2 trial, which met its co-primary endpoints, participants achieved significant body weight reduction of up to 13.1% versus 3.1% in the placebo arm, after 76 weeks of treatment with survodutide in people with type 2 diabetes, a population in which weight loss is typically more challenging.¹
Detailed results from the

Zealand Pharma announces Boehringer Ingelheim’s survodutide achieves up to 13.1% weight loss in new Phase III trial, alongside significant improvements in glycemic control in people with obesity and

Thu, 01 Oct 2026 03:30:00 -0400

Company announcement – No. 52 / 2026

In the SYNCHRONIZE-2 trial, which met its co-primary endpoints, participants achieved significant body weight reduction of up to 13.1% versus 3.1% in the placebo arm, after 76 weeks of treatment with survodutide in people with type 2 diabetes, a population in which weight loss is typically more challenging.¹
Detailed results from the

Total number of shares and voting rights in Zealand Pharma as of September 30, 2026

Wed, 30 Sep 2026 16:00:00 -0400

Company announcement – No. 51 / 2026

Total number of shares and voting rights in Zealand Pharma as of September 30, 2026

Copenhagen, Denmark, September 30, 2026 – Zealand Pharma A/S (“Zealand Pharma” or "the Company") (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, today announces, in accordance with section 32 of the Danish Capital Markets Act, the total number of shares and voting rights in the Company at the end of a calendar month during which changes to its share capital have occurred.

In Company Announcement No. 47 /

Total number of shares and voting rights in Zealand Pharma as of September 30, 2026

Wed, 30 Sep 2026 16:00:00 -0400

Company announcement – No. 51 / 2026

Total number of shares and voting rights in Zealand Pharma as of September 30, 2026

In Company Announcement No. 47 /

Zealand Pharma publishes Phase 2 petrelintide trial results in The Lancet

Tue, 29 Sep 2026 18:03:16 -0400

Zealand Pharma A/S (Nasdaq: ZEAL) announced that results from its Phase 2 ZUPREME-1 trial evaluating petrelintide, an investigational weight management treatment, have been published in The Lancet Diabetes & Endocrinology. Additional data from the trial were presented at the 62nd Annual Meeting of the European Association for the Study of Diabetes (EASD) on September 30, 2026.

The randomized, double-blind, placebo-controlled trial enrolled 485 adults with obesity or overweight and weight-related comorbidities across 32 sites in the United States, Poland, and Romania. Participants received once-weekly subcutaneous injections of petrelintide at doses ranging from 1.0 mg to 9.0 mg, or placebo, over 42

Zealand Pharma to present additional data from Phase 2 ZUPREME-1 trial for petrelintide at EASD 2026 and announces publication of trial results in The Lancet Diabetes & Endocrinology

Tue, 29 Sep 2026 18:03:00 -0400

Press release – No. 18 / 2026

Zealand Pharma to present additional data from Phase 2 ZUPREME-1 trial for petrelintide at EASD 2026 and announces publication of trial results in The Lancet Diabetes & Endocrinology

Treatment with petrelintide was associated with clinically meaningful, double-digit weight loss, with a gastrointestinal tolerability profile comparable to placebo
Treatment was associated with significant improvements in cardiometabolic disease risk factors, including reductions in pulse rate, high-sensitivity C-reactive protein and waist circumference
Additional results from the ZUPREME-1 study will be presented in an oral presentation

Zealand Pharma to present additional data from Phase 2 ZUPREME-1 trial for petrelintide at EASD 2026 and announces publication of trial results in The Lancet Diabetes & Endocrinology

Tue, 29 Sep 2026 18:03:00 -0400

Press release – No. 18 / 2026

Zealand Pharma to present additional data from Phase 2 ZUPREME-1 trial for petrelintide at EASD 2026 and announces publication of trial results in The Lancet Diabetes & Endocrinology

Treatment with petrelintide was associated with clinically meaningful, double-digit weight loss, with a gastrointestinal tolerability profile comparable to placebo
Treatment was associated with significant improvements in cardiometabolic disease risk factors, including reductions in pulse rate, high-sensitivity C-reactive protein and waist circumference
Additional results from the ZUPREME-1 study will be presented in an oral presentation

Zealand Pharma - Transactions related to share buy-back program (week 39, 2026)

Mon, 28 Sep 2026 11:00:00 -0400

Company announcement No. 50 / 2026

Zealand Pharma - Transactions related to share buy-back program (week 39, 2026)

Copenhagen, Denmark, September 28, 2026 – Zealand Pharma A/S ("the Company" or “Zealand Pharma”) (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, today reports transactions related to its share buy-back program (the “Program”) for week 39 (September 21 - September 25, 2026).

The Program is carried out in accordance with Article 5 of Regulation (EU) No 596/2014 (the Market Abuse Regulation, “MAR”) and Commission Delegated Regulation (EU) 2016/1052 (the “Safe

Zealand Pharma - Transactions related to share buy-back program (week 39, 2026)

Mon, 28 Sep 2026 11:00:00 -0400

Company announcement No. 50 / 2026

Zealand Pharma - Transactions related to share buy-back program (week 39, 2026)

The Program is carried out in accordance with Article 5 of Regulation (EU) No 596/2014 (the Market Abuse Regulation, “MAR”) and Commission Delegated Regulation (EU) 2016/1052 (the “Safe

Zealand Pharma starts Phase 3 trials for obesity drug petrelintide

Tue, 22 Sep 2026 11:00:18 -0400

Zealand Pharma A/S (Nasdaq: ZEAL) has initiated a global registrational Phase 3 program, called ZUPREME, to evaluate the efficacy and safety of its once-weekly obesity drug petrelintide, the Copenhagen-based biotechnology company announced.

The Phase 3a program, conducted with partner Roche, consists of three trials expected to enroll approximately 7,000 participants in total. ZUPREME-3 will enroll around 3,900 participants with overweight or obesity without type 2 diabetes. ZUPREME-4 will enroll approximately 600 participants with overweight or obesity and type 2 diabetes. ZUPREME-5 will enroll around 2,500 participants with overweight or obesity and established cardiovascular disease, with or without type 2 diabetes.

Each trial

Zealand Pharma announces initiation of the registrational Phase 3 ZUPREME program of petrelintide in people with overweight or obesity

Tue, 22 Sep 2026 11:00:00 -0400

Press release – No. 17 / 2026

Zealand Pharma announces initiation of the registrational Phase 3 ZUPREME program of petrelintide in people with overweight or obesity

The Phase 3 initiation marks a defining step toward establishing petrelintide as a future first-choice therapy for millions of people living with overweight or obesity
The global Phase 3a ZUPREME program consists of three trials, designed to support marketing applications for petrelintide monotherapy in chronic weight management
The Phase 3a program builds on positive Phase 2 results, which demonstrated double-digit weight loss with a tolerability profile largely

Zealand Pharma announces initiation of the registrational Phase 3 ZUPREME program of petrelintide in people with overweight or obesity

Tue, 22 Sep 2026 11:00:00 -0400

Press release – No. 17 / 2026

Zealand Pharma announces initiation of the registrational Phase 3 ZUPREME program of petrelintide in people with overweight or obesity

The Phase 3 initiation marks a defining step toward establishing petrelintide as a future first-choice therapy for millions of people living with overweight or obesity
The global Phase 3a ZUPREME program consists of three trials, designed to support marketing applications for petrelintide monotherapy in chronic weight management
The Phase 3a program builds on positive Phase 2 results, which demonstrated double-digit weight loss with a tolerability profile largely

Zealand Pharma - Transactions related to share buy-back program (week 38, 2026)

Mon, 21 Sep 2026 11:00:00 -0400

Company announcement No. 49 / 2026

Zealand Pharma - Transactions related to share buy-back program (week 38, 2026)

Copenhagen, Denmark, September 21, 2026 – Zealand Pharma A/S ("the Company" or “Zealand Pharma”) (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, today reports transactions related to its share buy-back program (the “Program”) for week 38 (September 14 - September 18, 2026).

The Program is carried out in accordance with Article 5 of Regulation (EU) No 596/2014 (the Market Abuse Regulation, “MAR”) and Commission Delegated Regulation (EU) 2016/1052 (the “Safe

Zealand Pharma - Transactions related to share buy-back program (week 38, 2026)

Mon, 21 Sep 2026 11:00:00 -0400

Company announcement No. 49 / 2026

Zealand Pharma - Transactions related to share buy-back program (week 38, 2026)

The Program is carried out in accordance with Article 5 of Regulation (EU) No 596/2014 (the Market Abuse Regulation, “MAR”) and Commission Delegated Regulation (EU) 2016/1052 (the “Safe

Zealand Pharma gets EU recommendation for short bowel syndrome drug

Fri, 18 Sep 2026 06:11:16 -0400

Zealand Pharma A/S (Nasdaq: ZEAL) announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has issued a positive opinion recommending marketing authorization for Zeydovio (glepaglutide) for the treatment of adults with short bowel syndrome.

The recommendation is based on data from the pivotal Phase 3 EASE-1 trial, in which twice-weekly glepaglutide reduced total weekly parenteral support volume by 5.13 liters per week, compared to 2.85 liters per week in the placebo group. In that trial, 65.7% of patients receiving glepaglutide twice weekly achieved at least a 20% reduction in weekly parenteral support volume after

Zealand Pharma receives positive CHMP opinion for Zeydovio™ (glepaglutide) for the treatment of short bowel syndrome

Fri, 18 Sep 2026 06:10:43 -0400

Press release – No. 16 / 2026

Zealand Pharma receives positive CHMP opinion for Zeydovio™ (glepaglutide) for the treatment of short bowel syndrome

The CHMP of the European Medicines Agency has recommended the approval of Zeydovio™ (glepaglutide) for the treatment of short bowel syndrome
The positive CHMP opinion marks the first major advancement in short bowel syndrome treatment in Europe in more than a decade
Zeydovio’s™ evidenced efficacy combined with its simple delivery, positions it as a transformative therapy for people living with short bowel syndrome
Two thirds of patients

Zealand Pharma receives positive CHMP opinion for Zeydovio™ (glepaglutide) for the treatment of short bowel syndrome

Fri, 18 Sep 2026 06:10:43 -0400

Press release – No. 16 / 2026

Zealand Pharma receives positive CHMP opinion for Zeydovio™ (glepaglutide) for the treatment of short bowel syndrome

The CHMP of the European Medicines Agency has recommended the approval of Zeydovio™ (glepaglutide) for the treatment of short bowel syndrome
The positive CHMP opinion marks the first major advancement in short bowel syndrome treatment in Europe in more than a decade
Zeydovio’s™ evidenced efficacy combined with its simple delivery, positions it as a transformative therapy for people living with short bowel syndrome
Two thirds of patients

Elvinix Secures Exclusive License to Advance Novel Peptide Therapy Aimed at Restoring Insulin Production in Type 1 Diabetes

Tue, 15 Sep 2026 07:00:00 -0400

The company plans to advance the licensed GLP-1/gastrin dual-agonist peptide portfolio from Zealand Pharma as a disease-modifying therapy to regenerate and protect endogenous beta-cell mass in patients with type 1 diabetes.

DOVER, Del.--(BUSINESS WIRE)-- Elvinix Inc., a biopharmaceutical company developing a regenerative, disease-modifying therapy for type 1 diabetes (T1D), today announced an exclusive license agreement with Zealand Pharma A/S (Nasdaq Copenhagen: ZEAL), granting Elvinix the rights to develop and commercialize Zealand’s GLP-1/gastrin dual-agonist peptide portfolio.

Approximately 9.5 million people worldwide live with T1D, a number that rises each year.(1) Elvinix is developing a novel, disease-modifying therapy designed to regenerate